Eng-Wong J et al. - In high-risk premenopausal women, mammographic density did not change on raloxifene, whereas MRIV significantly declined. The findings suggest that MRIV is a promising surrogate biomarker in premenopausal women at increased risk for breast cancer and should be investigated further in breast cancer prevention trials.